Cargando…
Induced Pluripotent Stem Cells to Model Juvenile Myelomonocytic Leukemia: New Perspectives for Preclinical Research
Juvenile myelomonocytic leukemia (JMML) is a malignant myeloproliferative disorder arising in infants and young children. The origin of this neoplasm is attributed to an early deregulation of the Ras signaling pathway in multipotent hematopoietic stem/progenitor cells. Since JMML is notoriously refr...
Autores principales: | Wehbe, Zeinab, Ghanjati, Foued, Flotho, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465353/ https://www.ncbi.nlm.nih.gov/pubmed/34571984 http://dx.doi.org/10.3390/cells10092335 |
Ejemplares similares
-
Current Treatment of Juvenile Myelomonocytic Leukemia
por: Mayerhofer, Christina, et al.
Publicado: (2021) -
Proteomic Analysis
of an Induced Pluripotent Stem
Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia
por: Pearson, Stella, et al.
Publicado: (2019) -
CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia
por: Fluhr, Silvia, et al.
Publicado: (2016) -
Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia
por: Stieglitz, Elliot, et al.
Publicado: (2017) -
P1000: JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) INHIBITS T CELL PROLIFERATION VIA THE ECTONUCLEOTIDASE CD39 AND THE PURINERGIC NETWORK
por: Rajak, Jovana, et al.
Publicado: (2023)